BIOMARIN PHARMACEUTICAL INC Reclassification from AOCI, Current Period, before Tax, Attributable to Parent
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Reclassification from AOCI, Current Period, before Tax, Attributable to Parent of -$4.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC reclassification from aoci, current period, before tax, attributable to parent for the quarter ending 2026-06-30 was -$4.05M.
- BIOMARIN PHARMACEUTICAL INC reclassification from aoci, current period, before tax, attributable to parent for the quarter ending 2026-03-31 was -$8.81M, a 188.65% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC reclassification from aoci, current period, before tax, attributable to parent for the quarter ending 2025-12-31 was -$16.73M, a 290.73% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC reclassification from aoci, current period, before tax, attributable to parent for the quarter ending 2025-09-30 was -$8.14M, a 330.11% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC reclassification from aoci, current period, before tax, attributable to parent for fiscal 2025 was -$15.47M, a 204.05% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC reclassification from aoci, current period, before tax, attributable to parent for fiscal 2024 was $14.87M, a 8968.29% increase from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC reclassification from aoci, current period, before tax, attributable to parent for fiscal 2023 was $164.00K, a 99.55% decline from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC reclassification from aoci, current period, before tax, attributable to parent for fiscal 2022 was $36.62M.
| Period end | Reclassification from AOCI, Current Period, before Tax, Attributable to Parent 3 month | Reclassification from AOCI, Current Period, before Tax, Attributable to Parent 3 month as first filed | Reclassification from AOCI, Current Period, before Tax, Attributable to Parent 6 month | Reclassification from AOCI, Current Period, before Tax, Attributable to Parent 9 month | Reclassification from AOCI, Current Period, before Tax, Attributable to Parent 9 month as first filed | Reclassification from AOCI, Current Period, before Tax, Attributable to Parent 12 month | Reclassification from AOCI, Current Period, before Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$4.05M 10-Q · filed 2026-08-06 | -$12.87M 10-Q · filed 2026-08-06 | -$29.59M derived: sum of 3 quarters · filed 2026-08-06 | -$37.73M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | -$8.81M 10-Q · filed 2026-05-05 | -$25.54M derived: sum of 2 quarters · filed 2026-05-05 | -$33.67M derived: sum of 3 quarters · filed 2026-05-05 | -$34.22M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | -$16.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$24.86M derived: sum of 2 quarters · filed 2026-02-26 | -$25.41M derived: sum of 3 quarters · filed 2026-08-06 | -$15.47M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$8.14M 10-Q · filed 2025-10-28 | -$8.69M derived: sum of 2 quarters · filed 2026-08-06 | $1.25M 10-Q · filed 2025-10-28 | $10.02M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | -$549.00K 10-Q · filed 2026-08-06 | $9.39M 10-Q · filed 2026-08-06 | $18.16M derived: sum of 3 quarters · filed 2026-08-06 | $21.70M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $9.94M 10-Q · filed 2026-05-05 | $18.71M derived: sum of 2 quarters · filed 2026-05-05 | $22.25M derived: sum of 3 quarters · filed 2026-05-05 | $25.43M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | $8.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $12.31M derived: sum of 2 quarters · filed 2026-02-26 | $15.49M derived: sum of 3 quarters · filed 2026-02-26 | $14.87M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $3.54M 10-Q · filed 2025-10-28 | $6.72M derived: sum of 2 quarters · filed 2025-10-28 | $6.10M 10-Q · filed 2025-10-28 | $6.33M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | $3.18M 10-Q · filed 2025-08-05 | $2.57M 10-Q · filed 2025-08-05 | $2.79M derived: sum of 3 quarters · filed 2026-02-26 | -$935.00K derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | -$615.00K 10-Q · filed 2025-05-02 | -$388.00K derived: sum of 2 quarters · filed 2026-02-26 | -$4.12M derived: sum of 3 quarters · filed 2026-02-26 | -$3.46M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.50M derived: sum of 2 quarters · filed 2026-02-26 | -$2.85M derived: sum of 3 quarters · filed 2026-02-26 | $164.00K 10-K · filed 2026-02-26 | |||
| 2023-09-30 | -$3.73M 10-Q · filed 2024-10-31 | -$3.08M derived: sum of 2 quarters · filed 2024-10-31 | -$63.00K 10-Q · filed 2024-10-31 | $16.90M derived: sum of 4 quarters · filed 2025-02-24 | |||
| 2023-06-30 | $651.00K 10-Q · filed 2024-08-05 | $3.67M 10-Q · filed 2024-08-05 | $20.63M derived: sum of 3 quarters · filed 2025-02-24 | $31.97M derived: sum of 4 quarters · filed 2025-02-24 | |||
| 2023-03-31 | $3.01M 10-Q · filed 2024-04-26 | $19.97M derived: sum of 2 quarters · filed 2025-02-24 | $31.32M derived: sum of 3 quarters · filed 2025-02-24 | $35.45M derived: sum of 4 quarters · filed 2025-02-24 | |||
| 2022-12-31 | $16.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $28.30M derived: sum of 2 quarters · filed 2025-02-24 | $32.43M derived: sum of 3 quarters · filed 2025-02-24 | $36.62M 10-K · filed 2025-02-24 | |||
| 2022-09-30 | $11.34M 10-Q · filed 2023-11-02 | $15.47M derived: sum of 2 quarters · filed 2023-11-02 | $19.66M 10-Q · filed 2023-11-02 | $23.16M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2022-06-30 | $4.13M 10-Q · filed 2023-08-02 | $8.32M 10-Q · filed 2023-08-02 | $11.82M derived: sum of 3 quarters · filed 2024-02-26 | $11.95M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2022-03-31 | $4.19M 10-Q · filed 2023-04-28 | $7.69M derived: sum of 2 quarters · filed 2024-02-26 | $7.83M derived: sum of 3 quarters · filed 2024-02-26 | $5.49M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2021-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $3.63M derived: sum of 2 quarters · filed 2024-02-26 | $1.30M derived: sum of 3 quarters · filed 2024-02-26 | -$1.45M 10-K · filed 2024-02-26 | |||
| 2021-09-30 | $133.00K 10-Q · filed 2022-10-28 | -$2.20M derived: sum of 2 quarters · filed 2022-10-28 | -$4.95M 10-Q · filed 2022-10-28 | -$4.25M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-06-30 | -$2.33M 10-Q · filed 2022-08-04 | -$5.09M 10-Q · filed 2022-08-04 | -$4.38M derived: sum of 3 quarters · filed 2023-02-27 | -$2.50M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-03-31 | -$2.75M 10-Q · filed 2022-04-29 | -$2.05M derived: sum of 2 quarters · filed 2023-02-27 | -$169.00K derived: sum of 3 quarters · filed 2023-02-27 | $6.32M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2020-12-31 | $705.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $2.58M derived: sum of 2 quarters · filed 2023-02-27 | $9.08M derived: sum of 3 quarters · filed 2023-02-27 | $13.73M 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $1.88M 10-Q · filed 2021-10-29 | $8.37M derived: sum of 2 quarters · filed 2021-10-29 | $13.03M 10-Q · filed 2021-10-29 | $19.59M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-06-30 | $6.49M 10-Q · filed 2021-07-30 | $11.15M 10-Q · filed 2021-07-30 | $17.72M derived: sum of 3 quarters · filed 2022-02-25 | $22.52M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-03-31 | $4.66M 10-Q · filed 2021-04-30 | $11.22M derived: sum of 2 quarters · filed 2022-02-25 | $16.03M derived: sum of 3 quarters · filed 2022-02-25 | $19.54M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | $6.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $11.38M derived: sum of 2 quarters · filed 2022-02-25 | $14.89M derived: sum of 3 quarters · filed 2022-02-25 | $15.85M 10-K · filed 2022-02-25 | |||
| 2019-09-30 | $4.81M 10-Q · filed 2020-11-06 | $8.32M derived: sum of 2 quarters · filed 2020-11-06 | $9.29M 10-Q · filed 2020-11-06 | $10.16M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-06-30 | $3.51M 10-Q · filed 2020-08-05 | $4.48M 10-Q · filed 2020-08-05 | $5.35M derived: sum of 3 quarters · filed 2021-02-26 | $10.88M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-03-31 | $966.00K 10-Q · filed 2020-05-01 | $1.84M derived: sum of 2 quarters · filed 2021-02-26 | $7.36M derived: sum of 3 quarters · filed 2021-02-26 | $4.70M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2018-12-31 | $874.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2021-02-26 | $6.40M derived: sum of 2 quarters · filed 2021-02-26 | $3.74M derived: sum of 3 quarters · filed 2021-02-26 | -$2.05M 10-K · filed 2021-02-26 | |||
| 2018-09-30 | $5.52M 10-Q/A · filed 2019-11-04 | $2.86M derived: sum of 2 quarters · filed 2019-11-04 | -$2.92M 10-Q/A · filed 2019-11-04 | -$7.54M derived: sum of 4 quarters · filed 2019-11-04 | |||
| 2018-06-30 | -$2.66M 10-Q · filed 2019-08-02 | -$8.44M 10-Q · filed 2019-08-02 | -$13.07M derived: sum of 3 quarters · filed 2019-08-02 | -$16.77M derived: sum of 4 quarters · filed 2019-08-02 | |||
| 2018-03-31 | -$5.79M 10-Q · filed 2019-04-29 | -$10.41M derived: sum of 2 quarters · filed 2019-04-29 | -$14.11M derived: sum of 3 quarters · filed 2019-04-29 | -$13.41M derived: sum of 4 quarters · filed 2019-04-29 | |||
| 2017-12-31 | -$4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$8.32M derived: sum of 2 quarters · filed 2019-02-28 | -$7.63M derived: sum of 3 quarters · filed 2019-02-28 | -$1.86M 10-K · filed 2019-02-28 | |||
| 2017-09-30 | -$3.70M 10-Q · filed 2018-10-26 | -$3.00M derived: sum of 2 quarters · filed 2018-10-26 | $2.76M 10-Q · filed 2018-10-26 | $6.03M derived: sum of 4 quarters · filed 2018-10-26 | |||
| 2017-06-30 | $695.00K 10-Q · filed 2018-08-03 | $6.46M 10-Q · filed 2018-08-03 | $9.73M derived: sum of 3 quarters · filed 2018-08-03 | $11.22M derived: sum of 4 quarters · filed 2018-08-03 | |||
| 2017-03-31 | $5.77M 10-Q · filed 2018-04-27 | $9.04M derived: sum of 2 quarters · filed 2018-04-27 | $10.53M derived: sum of 3 quarters · filed 2018-04-27 | $8.30M derived: sum of 4 quarters · filed 2018-04-27 | |||
| 2016-12-31 | $3.27M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $4.76M derived: sum of 2 quarters · filed 2018-02-26 | $2.54M derived: sum of 3 quarters · filed 2018-02-26 | $10.16M 10-K · filed 2018-02-26 | -$10.16M 10-K · filed 2017-02-27 | ||
| 2016-09-30 | $1.49M 10-Q · filed 2017-10-31 | -$1.49M 10-Q · filed 2016-11-03 | -$731.00K derived: sum of 2 quarters · filed 2017-10-31 | $6.89M 10-Q · filed 2017-10-31 | -$6.89M 10-Q · filed 2016-11-03 | $3.53M derived: sum of 4 quarters · filed 2017-10-31 | |
| 2016-06-30 | -$2.22M 10-Q · filed 2017-08-02 | $5.40M 10-Q · filed 2017-08-02 | $2.04M derived: sum of 3 quarters · filed 2017-08-02 | -$3.16M derived: sum of 4 quarters · filed 2017-08-02 | |||
| 2016-03-31 | $7.62M 10-Q · filed 2017-05-04 | $4.26M derived: sum of 2 quarters · filed 2017-05-04 | -$937.00K derived: sum of 3 quarters · filed 2017-05-04 | ||||
| 2015-12-31 | -$3.36M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | -$8.56M derived: sum of 2 quarters · filed 2017-02-27 | -$21.48M 10-K · filed 2017-02-27 | ||||
| 2015-09-30 | -$5.20M 10-Q · filed 2016-11-03 | -$18.12M 10-Q · filed 2016-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |